Edition:
United Kingdom

Auris Medical Holding AG (EARS.OQ)

EARS.OQ on NASDAQ Stock Exchange Capital Market

0.28USD
16 Jul 2018
Change (% chg)

$-0.02 (-5.41%)
Prev Close
$0.30
Open
$0.30
Day's High
$0.31
Day's Low
$0.28
Volume
753,084
Avg. Vol
114,163
52-wk High
$9.50
52-wk Low
$0.28

Latest Key Developments (Source: Significant Developments)

Auris Medical Prices $7 Million Public Offering
Friday, 13 Jul 2018 

July 12 (Reuters) - Auris Medical Holding AG ::AURIS MEDICAL PRICES $7 MILLION PUBLIC OFFERING.AURIS MEDICAL HOLDING- ANNOUNCED PRICING OF UNDERWRITTEN PUBLIC OFFERING OF 17.9 MILLION SHARES, SERIES A WARRANTS TO PURCHASE 6.2 MILLION COMMON SHARES.COMBINED PUBLIC OFFERING PRICE PER UNIT IS $0.39.AURIS MEDICAL -PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF SERIES WARRANTS TO PURCHASE 6.3 MILLION COMMON SHARES.AURIS MEDICAL -PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF SERIES B WARRANTS TO PURCHASE 4.5 MILLION COMMON SHARES.  Full Article

Auris Medical Provides Q1 Loss Per Share CHF 0.30
Tuesday, 15 May 2018 

May 15 (Reuters) - Auris Medical Holding AG ::AURIS MEDICAL PROVIDES BUSINESS AND STRATEGY UPDATE AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE CHF 0.30.AURIS-INITIATING PROJECT AM-201 FOR TREATMENT OF HISTAMINERGIC RECEPTOR MEDIATED WEIGHT GAIN,DROWSINESS IN PATIENTS TREATED BY ANTIPSYCHOTIC MEDICATION.REDUCING LEVEL OF OPERATING EXPENSES, WHICH CO BELIEVES WILL RESULT IN REDUCTION OF CASH BURN RATE.CONTINUES TO EXPECT THAT ITS OPERATING EXPENSES IN 2018 WILL BE IN RANGE OF CHF 10 TO 12 MILLION.  Full Article

Auris Medical Announces Further Results From Healos Phase 3 Trial
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Auris Medical Holding Ag ::AURIS MEDICAL HOLDING AG SAYS ANNOUNCED FURTHER CLINICAL RESULTS FROM THE HEALOS PHASE 3 CLINICAL TRIAL, PROVIDES UPDATE ON AM-111 DEVELOPMENT PROGRAM.AURIS MEDICAL HOLDING AG SAYS AM-111 TREATED PATIENTS HAD A LOWER INCIDENCE OF NO HEARING IMPROVEMENT- SEC FILING.AURIS MEDICAL HOLDING SAYS POST-HOC ANALYSES OF TOP-LINE DATA REVEALED CLINICALLY AND STATISTICALLY SIGNIFICANT HEARING IMPROVEMENT WITH AM-111.AURIS MEDICAL HOLDING SAYS PLANS TO DISCUSS ACCUMULATED SAFETY AND EFFICACY DATA AND REGULATORY PATHWAY WITH FDA AND EMA IN Q2 OF 2018..  Full Article

Auris Medical Reports Q3 Loss Per Share CHF 0.14
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Auris Medical Holding AG ::AURIS MEDICAL REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q3 LOSS PER SHARE CHF 0.14.‍NET LOSS FOR Q3 OF 2017 WAS CHF 6.0 MILLION, OR CHF 0.14 PER SHARE​.EXPECTS THAT ITS OPERATING EXPENSES IN 2017 WILL BE LOWER THAN PREVIOUS GUIDANCE OF CHF 28 TO 32 MILLION​.‍EXPECTS THAT EXISTING CASH AND CASH EQUIVALENTS WILL ENABLE FUNDING OF OPERATIONS INTO Q2 OF 2018​.  Full Article

Auris Medical Reports Top-Line Results from Phase 3 Trial of AM-111 in Sudden Deafness
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Auris Medical Holding Ag ::AURIS MEDICAL HOLDING AG SAYS ANNOUNCED TOP-LINE RESULTS FROM THE HEALOS PHASE 3 CLINICAL TRIAL OF AM-111 IN SEVERE TO PROFOUND SUDDEN DEAFNESS.AURIS MEDICAL HOLDING AG SAYS HEALOS TRIAL DID NOT MEET PRIMARY EFFICACY ENDPOINT IN OVERALL STUDY POPULATION.AURIS MEDICAL SAYS IN HEALOS TRIAL, CLINICALLY AND STATISTICALLY SIGNIFICANT IMPROVEMENT IN SUBPOPULATION OF PATIENTS WITH PROFOUND ACUTE HEARING LOSS.AURIS MEDICAL SAYS BASED ON FINDINGS FROM HEALOS TRIAL, CONCLUDED THAT SIMILAR DESIGN OF ONGOING ASSENT TRIAL NO LONGER ADEQUATE FOR TESTING AM-111.AURIS MEDICAL HOLDING AG SAYS BASED ON FINDINGS FROM HEALOS TRIAL, ASSENT TRIAL WILL BE TERMINATED EARLY.  Full Article

Auris Medical Holding AG files for resale of up to 7.2 mln common shares
Thursday, 12 Oct 2017 

Oct 12 (Reuters) - Auris Medical Holding Ag :Auris Medical Holding AG files for resale of up to 7.2 million common shares by selling shareholder, LPC Capital Fund Llc‍​ - SEC Filing.  Full Article

Auris Medical announces share purchase agreements with Lincoln Park Capital Fund
Wednesday, 11 Oct 2017 

Oct 11 (Reuters) - Auris Medical Holding Ag :Auris Medical announces share purchase agreements with Lincoln Park Capital Fund, Llc.Auris Medical Holding AG - ‍execution of two share purchase agreements for up to $15.0 million with Lincoln Park Capital Fund, Llc​.Auris Medical Holding - ‍pursuant to agreement dated Oct 10 Auris Medical may require LPC, to subscribe for up to $13.5 million worth of its common shares​.Auris Medical Holding- on Oct 10, Auris entered into purchase agreement with LPC as per which LPC subscribed for $1.5 million worth of Auris's shares​.  Full Article

Auris medical announces proposed public offering of common shares and warrants
Tuesday, 14 Feb 2017 

Auris Medical Holding Ag : Auris medical announces proposed public offering of common shares and warrants .Intends to use net proceeds from offering for working capital and general corporate purposes.  Full Article

Auris reports top-line results from TACTT2 trial with Keyzilen
Thursday, 18 Aug 2016 

Auris Medical Holding AG : Reports top-line results from TACTT2 trial with Keyzilen in acute inner ear tinnitus . Treatment with Keyzilen did not demonstrate statistically significant difference in tinnitus improvement versus placebo . TACTT2 trial did not meet its co-primary efficacy endpoints . Top-Line results from the phase 3 TACTT3 trial expected in the fourth quarter of 2016 . Keyzilen was well tolerated with no drug-related serious adverse events Further company coverage: [EARS.O] ((bangalore.newsroom@thomsonreuters.com;)).  Full Article

Auris medical Q2 loss per share CHF 0.25
Thursday, 18 Aug 2016 

Auris Medical Holding AG : Auris Medical provides business update and reports second quarter 2016 financial results . Q2 loss per share CHF 0.25 . Continues to expect that its operating expenses in 2016 will be in range of CHF 33.0 to 38.0 million .Existing cash and cash equivalents, including $12.5 million loan, will enable funding of operations until year-end 2017.  Full Article

BRIEF-Auris Medical Receives Positive Scientific Advice From EMA On Development Plan And Regulatory Pathway For AM-111

* AURIS MEDICAL RECEIVES POSITIVE SCIENTIFIC ADVICE FROM EMA ON DEVELOPMENT PLAN AND REGULATORY PATHWAY FOR AM-111